REG - GenIP PLC Tekcapital plc - Corporate Update & 2025 Outlook

TekcapitalAnnouncement

13/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM4224Aa&default-theme=true

RNS Number : 4224A  GenIP PLC  13 March 2025

 

 

13 March 2025

 

GenIP Plc

("GenIP" or the "Company")

 

Corporate Update

 

GenIP plc, a technology business providing Generative Artificial Intelligence
(GenAI) services to help research organisations and corporations commercialise
their innovations, is pleased to provide the following corporate update and
outlook for the year ahead.

 

Highlights

 

●    Significant Commercial Progress: Since the launch of GenAI enhanced
services in September 2024, GenIP has secured Invention Evaluator orders
(including prepaid advance orders for future drawdown) for over 450 analytical
assessments and has completed two Vortechs executive hires with four new
searches underway.

 

●    Robust Order Pipeline: Following the launch of an extensive
marketing campaign in December 2024, the Company has received a number of
promising leads and believes the conversion of its current sales pipeline will
lead to a step-change in order flow and revenue generation.

 

●    Global Expansion: International interest in GenIP's solutions is
growing. The Company has delivered Invention Evaluator reports to
organisations in over 25 countries across six continents, and the pipeline
continues to expand to new territories. Demonstrating the global appeal of its
services, GenIP has significant bids in progress with two leading institutions
in Asia following our participation in a major industry event in the region.

 

●    Product Development: As a result of deep engagement with new and
existing customers, GenIP is developing a new range of AI-enhanced solutions
to serve the technology transfer market. It is intended that GenIP's new
products will leverage the existing AI analytics infrastructure and complement
current offering by meeting additional requirements of research organisations
seeking to accelerate the commercialisation of their technological
discoveries.

 

 

AUTM 2025 Annual Meeting

 

Building on recent event sponsorships in Asia and Latin America that led to
new Invention Evaluator orders, GenIP sponsored and attended the AUTM Annual
Meeting in the US in March 2025. AUTM is a leading global platform for
advancing knowledge in Intellectual Property, Technology Transfer, and
Innovation. GenIP connected with representatives of universities, research
institutions, corporations, and investment firms and believes the event will
result in additional orders.

 

 

2025 Outlook

 

GenIP is well-positioned to capitalise on the growing demand for AI-enhanced
solutions in the technology transfer market. The Company has clear revenue
visibility, a strong order book, and a growing sales pipeline. GenIP is
actively collaborating with the industry to continuously improve its services
and is pursuing the expansion of its offering with new products nearing their
launch. Customers pay in advance for Invention Evaluator report orders,
providing the Company with operating cash flow and future revenue visibility,
with revenue recognised upon report production by GenIP and delivery to the
client. Typically, prepayments are utilised approximately 50% within the first
12 months and the balance over the following 12-18 months. Historically, there
was no time limit for utilisation of the prepaid reports. To accelerate the
utilisation the Company has implemented new strategies including a fixed
period during which the prepaid orders need to be used. Our expanding client
base and the anticipated introduction of new products position the Company
favourably for significant growth. GenIP retains ample financial flexibility
to capitalise on emerging opportunities.

 

Since the last corporate update, GenIP has completed two executive search
assignments and secured four new searches. The Directors anticipate increasing
demand for Vortechs services as a result of the ongoing marketing efforts and
the current prospective assignments being progressed.

 

Lord Willetts, Chairman of GenIP, commented:

 

"As Chairman of the Board, I'm delighted to see GenIP's solid commercial
progress and global reach, which is a testament to the value our AI-enhanced
solutions bring to the technology transfer market. The combination of
sophisticated analytics with expert human insights has the potential to be a
winning formula, providing support to universities and corporations in
navigating the complexities of commercialising innovation. In a world where
the pace of technological advancement is ever-increasing, GenIP is
well-positioned to play a role in ensuring that the most promising discoveries
reach their potential."

 

For further information regarding GenIP, please visit www.genip.ai
(http://www.genip.ai/) , or contact:

 

 GenIP Plc                                                                 Via Redchurch Communications

 Melissa Cruz, CEO

 Beaumont Cornish Limited (Nominated Adviser)                              Tel:  +44 (0) 20 7628 3396

 Roland Cornish / Asia Szusciak / Andrew Price

 Novum Securities Limited (Broker)                                         Tel: +44 (0)20 7399 9425

 Jon Belliss                                                               JBelliss@novumsecurities.com

 Redchurch Communications (Financial PR)                                   genip@weareredchurch.com (mailto:genip@weareredchurch.com)

 John Casey

The information communicated within this announcement is deemed to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No
596/2014 which is part of UK law by virtue of the European Union (Withdrawal)
Act 2018.

 

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated
Adviser and is authorised and regulated by the FCA. Beaumont Cornish's
responsibilities as the Company's Nominated Adviser, including a
responsibility to advise and guide the Company on its responsibilities under
the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed
solely to the London Stock Exchange. Beaumont Cornish is not acting for and
will not be responsible to any other persons for providing protections
afforded to customers of Beaumont Cornish nor for advising them in relation to
the proposed arrangements described in this announcement or any matter
referred to in it.

 

Notes to Editors

 

About GenIP

 

GenIP provides generative artificial intelligence (GenAI) analytic services to
help companies, research institutions and venture funds assess and
commercialise new discoveries. GenIP combines expert human technical review
with GenAI algorithms to provide insightful and verified services.

 

GenIP provides two complementary platform-based services:

1.   Invention Evaluator: Provides bespoke research reports that assess the
market potential of new technological innovations and discoveries using
AI-driven proprietary software; and

 

2.   Vortechs: which is an executive recruitment platform that through
advanced machine learning algorithms and natural language processing
technologies assists in matching technology organisations with experienced
executives skilled in technology commercialisation.

 

The Company believes that its integrated GenAI service offerings will help
organisations to evaluate and commercialise their technological innovations.

Company Strategy

GenIP's goal is to be a leading Generative AI analytic services company. To
achieve this, the Company has established three strategic pillars:

 

●    Organically grow Invention Evaluator and Vortechs' revenue through
institutional and corporate connections as well as increase client pipeline
through marketing, advertising and social media spend.

●    Expand the Generative AI service offerings within Invention
Evaluator and Vortechs' to reach new customers and improve margins.

●    Bolt-on acquisitions of additional Generative AI services that are
helpful to our clients and have demonstrated initial market traction.

 

 

Forward looking statements

 

Certain statements contained in this announcement constitute forward-looking
statements. When used in this announcement, the words "may", "would", "could",
"will", "intend", "plan", "anticipate", "believe", "seek", "propose",
"estimate", "expect", and similar expressions, as they relate to the Company,
are intended to identify forward-looking statements. These statements include,
but are not limited to, statements regarding intentions, beliefs or current
expectations concerning, among other things, the Company's results of
operations, financial position, liquidity, prospects, growth, strategies and
expectations of the industry in which the Company operates.

 

Such statements reflect the Company's current views with respect to future
events and are subject to certain risks, uncertainties and assumptions. Many
factors could cause the Company's actual results, performance or achievements
to materially differ from those described in this announcement Should one or
more of these risks or uncertainties materialise, or should assumptions
underlying forward-looking statements prove incorrect, actual results may
differ materially from those described in this announcement as "intended",
"planned", "anticipated", "believed", "proposed", "estimated" or "expected".

 

For the avoidance of doubt, the contents of the Company's website and any
hyperlinks accessible from the Company's website are not incorporated by
reference into, and do not form part of, this announcement and investors
should not rely on them.

-ENDS-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDJTMITMTTBBIA